WASHINGTON, Jan. 17,
2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc.
(Vanda) (Nasdaq: VNDA) today announced the publication of an
article titled "Efficacy and Safety of Iloperidone in Bipolar
Mania: A Double-Blind, Placebo-Controlled Study" in the
Journal of Clinical Psychiatry.1 The findings of this
pivotal study have been submitted to the U.S. Food and Drug
Administration (FDA) as part of Vanda's supplemental New Drug
Application for Fanapt® in the treatment of bipolar I
disorder in adults. The FDA has set a Prescription Drug User Fee
Act target action date of April 2,
2024 for its decision.
References
- Torres R, Czeisler EL, Chadwick SR, et al. Efficacy and safety
of iloperidone in bipolar mania: a double-blind, placebo-controlled
study. J Clin Psychiatry. 2024;85(1):23m14966. Available
online: https://doi.org/10.4088/JCP.23m14966
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on
the development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of patients.
For more on Vanda Pharmaceuticals Inc., please visit
www.vandapharma.com and follow us on Twitter @vandapharma.
About Fanapt®
For full U.S. Prescribing Information for Fanapt®,
including indication, Boxed Warnings and Important Safety
Information, visit our Web site at www.fanapt.com.
Corporate Contact:
Kevin
Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-iloperidone-in-bipolar-mania-a-double-blind-placebo-controlled-study-in-the-journal-of-clinical-psychiatry-302037494.html
SOURCE Vanda Pharmaceuticals Inc.